Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT ...

On Thursday, TD Cowen analysts adjusted their price target for Eli Lilly (NYSE: NYSE: LLY) shares, reducing it to $960 from a previous target of $1,050.The analysts maintained a Buy rating for the ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... for the next line of drugs front ran the stock price. For example, in 2016 Lilly was trading 13 times the trailing 12 months ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Eli Lilly (NYSE: LLY) is encouraged by trial data for its latest weight-loss and diabetes medications. Should you invest $1,000 in Eli Lilly right now? Stock Advisor analyst team just identified what ...